APLT250117C500
- 0.30
- +0.01+3.45%
Applied Therapeutics Newsroom
William Blair Downgrades Applied Therapeutics(APLT.US) to Hold Rating
RBC Capital Maintains Applied Therapeutics(APLT.US) With Hold Rating, Cuts Target Price to $1.5
Applied Therapeutics Is Maintained at Sector Perform by RBC Capital
Applied Therapeutics Analyst Ratings
Buy Rating Maintained for Applied Therapeutics Amidst SORD Program Potential and Regulatory Challenges
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $13.00/Share From $11.00 by Citigroup
Citigroup Maintains Buy on Applied Therapeutics, Lowers Price Target to $8
Applied Therapeutics Is Maintained at Outperform by Baird
Baird Maintains Outperform on Applied Therapeutics, Lowers Price Target to $5
RBC Capital Downgrades Applied Therapeutics to Sector Perform, Lowers Price Target to $4
Applied Therapeutics Analyst Ratings
RBC Capital Initiates Applied Therapeutics(APLT.US) With Hold Rating, Announces Target Price $12
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Raises Target Price to $13
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12
Baird Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Positive Regulatory Outlook and Imminent PDUFA Date Justify Buy Rating for Applied Therapeutics
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12